Evidence map›Paper›PMID 40924921›Full record

ArticleBlood advances2026

Tumor microenvironment differences between diagnostic and relapsed classic Hodgkin lymphoma revealed by scRNA-seq.

Yifan Yin, Shinya Rai, Aixiang Jiang, Alexander Xu, Luke O'Brien, Adèle Telenius, Jan Delabie, Lauren Chong, Stacy Hung, Akil Merchant and 4 more

Abstract read
In one paragraph

Article in Blood advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yifan YinCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Shinya RaiCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Aixiang JiangCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-6153-7595
Alexander XuDepartment of Bioengineering, University of Maryland, College Park, MD.ORCID 0000-0003-4877-4358
Luke O'BrienCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Adèle TeleniusCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Jan DelabiePrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-5023-0689
Lauren ChongCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Stacy HungCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.
Akil MerchantCedars-Sinai Medical Center, Los Angeles, CA.ORCID 0000-0001-7472-822X
David W ScottCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-0435-5947
Kerry J SavageCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0002-5835-9863
Tomohiro AokiPrincess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.ORCID 0000-0001-6782-8361
Christian SteidlCentre for Lymphoid Cancer, BC Cancer, Vancouver, BC, Canada.ORCID 0000-0001-9842-9750

Funding

Spatially resolved, single cell biomarkers of B cell lymphomaR01CA266544 · NCI · CEDARS-SINAI MEDICAL CENTER · PI Akil Merchant · 2022 to 2026
$3.2M
NCI NIH HHS R01 CA266544
6 · The paper itself

Abstract

abstractClassical Hodgkin lymphoma (CHL) is characterized by a complex tumor microenvironment (TME) that supports disease progression. Although immune cell recruitment by Hodgkin and Reed-Sternberg (HRS) cells is well documented, the role of nonmalignant B cells in relapse remains unclear. Using single-cell RNA sequencing (scRNA-seq) on paired diagnostic and relapsed CHL samples, we identified distinct shifts in B-cell populations, particularly an enrichment of naïve B cells and a reduction of memory B cells in early-relapse CHL compared to late-relapse and newly diagnosed CHL. The enrichment of naïve B cells in early relapse biopsies was confirmed in independent validation cohorts using scRNA-seq and immunohistochemistry. Notably, naïve B cells in early-relapse samples exhibited high expression of LGALS9, an immunosuppressive gene encoding galectin-9, which binds to HAVCR2 (T-cell immunoglobulin and mucin domain-containing protein 3 [TIM-3]) on regulatory T cells (Tregs). Cell-cell interaction analysis revealed the importance of interactions between LGALS9+ naïve B cells and HAVCR2+ Tregs in the early-relapse setting. Spatial analysis by imaging mass cytometry confirmed close proximity of galectin-9-positive naïve B cells with TIM-3+ CD4+ T cells and HRS cells, pointing to their role in shaping an immunosuppressive niche. Our findings highlight a previously unrecognized population of galectin-9-positive naïve B cells with immunoregulatory potential in early-relapse CHL and provide new insights into the spatial and transcriptional architecture of the relapsed TME in CHL.

Indexed as

Hodgkin DiseaseRNA-SeqTumor MicroenvironmentB-LymphocytesFemaleGalectinsHepatitis A Virus Cellular Receptor 2HumansMaleNeoplasm Recurrence, LocalRecurrenceSingle-Cell AnalysisSingle-Cell Gene Expression AnalysisT-Lymphocytes, RegulatoryGalectinsHAVCR2 protein, humanHepatitis A Virus Cellular Receptor 2LGALS9 protein, human

Identifiers

PMID40924921
PMCPMC12803924

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.